Manufacturing

In recent years, CSL Behring has closely collaborated with its parent company CSL Limited to develop a number of novel recombinant hemophilia therapies. The new plant in Lengnau will manufacture these new therapies on a commercial scale and supply the markets worldwide. The treatment with recombinant coagulation factors will help hemophilia patients around the world to live a full life without limiting the quality of life despite their bleeding disorder.

 

Manufacturing of recombinant products

Our coagulation factor products are used to treat patients with a deficiency in natural blood proteins resulting in potentially life-threatening bleeding disorders. Some therapies designed to replace the deficient proteins are derived from human plasma. Recombinant therapies are made from genetically adapted cell cultures, where an original cell is modified (re-programmed) to produce specifically desired proteins. These proteins are harvested for use as therapies. This new process using recombinant expression technology will further reduce the risk of potential virus transmission. Together with our plasma-derived coagulation therapies, the recombinant development portfolio will offer new options to patients and will make CSL even more competitive in the coagulation marketplace.

 

Hemophilia

Hemophilia is a rare congenital and severe bleeding disorder. A hemophilia patient's blood does not clot properly because the coagulation factor VIII (hemophilia A) or IX (hemophilia B) are either deficient or dysfunctional. Hemophilia patients with acquired antibodies against coagulation factor VIII or IX need to be treated alternatively with factor VIIa in case of severe emergency bleedings. Acquired antibodies are also called inhibitors as they interfere with the biological function of specific coagulation factors.

 

Hemophilia A

  • Is caused by a deficiency in clotting factor VIII and primarily affects males
  • Approximately 1 in 10,000 people suffer from hemophilia A

Hemophilia B

  • Is caused by a deficiency in clotting factor IX and primarily affects males
  • Approximately 1 in 50,000 people suffer from hemophilia B

Learn more about hemophilia (website in German).

 

© 2017 CSL Behring